CyberKnife - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The cyberKnife market size is projected to expand from USD 267.93 million in 2025 and USD 275.11 million in 2026 to USD 427.66 million by 2031, registering a CAGR of 7.63% between 2026 to 2031. This report is Segmented by Product Type (CyberKnife System, Software Solutions, Services), Indication (Tumor and Cancer, Vascular Malformation, Other Indications), End User (Hospitals & Academic Medical Centers, Independent Radiotherapy Centers, Ambulatory/Outpatient Centers), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). Forecasts are Provided in Terms of Value (USD).

Global CyberKnife Market Trends and Insights

Rising Cancer Burden and Treatment Demand

The CyberKnife market is gaining support from the steady rise in cancer volume and case complexity across major care systems. The World Health Organization said annual global cancer cases are expected to exceed 35 million by 2050, which keeps long-term demand strong for precise radiation platforms that can absorb more patients without a matching increase in treatment infrastructure. This demand is especially relevant for brain metastases, vertebral metastases, and prostate cancer, where longer survival in primary oncology is increasing the number of patients who need focused local treatment. Australia’s cancer diagnoses are projected to rise from 212,332 cases to 318,285 by 2045, which supports the business case for expanding access to high-precision treatment networks. Austria also remains under-supplied in radiotherapy equipment, with availability 27% below the EU average and 34% below economic peers, which creates room for new CyberKnife market installations in under-served regions. As these supply gaps persist, the CyberKnife market is likely to benefit most in locations where cancer demand is rising faster than radiotherapy capacity.

Preference for Non-Invasive and Organ-Sparing Treatment

The CyberKnife market is also benefiting from the broader preference for non-invasive care that avoids surgery when clinical outcomes are comparable. CyberKnife’s Synchrony real-time motion-tracking capability helps clinicians treat thoracic, hepatic, and spinal targets with continuous adjustment for patient movement, which broadens its use beyond frame-based intracranial treatment. A 2025 long-term study of vestibular schwannoma patients reported 89.3% local control and 97.1% overall survival at 25 years after CyberKnife treatment, which reinforces confidence in durable organ-sparing management. A 2025 clinical study from Peking Union Medical College Hospital also found highly accurate dose delivery with minimal damage to surrounding tissue in pituitary adenoma and lung adenocarcinoma vertebral metastasis cases, which supports broader extracranial use. As a result, the CyberKnife market is gaining from a treatment preference that values precision, tissue preservation, and recovery outside the operating room.

High Capital Cost and Service Intensity

The CyberKnife market still faces a major barrier from the high upfront cost of system acquisition and the ongoing cost of support after installation. A typical system costs USD 5 million to USD 7 million before shielding construction and commissioning, which limits new projects to well-capitalized academic and tertiary providers. This burden becomes even more important after installation because service contracts, upgrades, and maintenance add recurring obligations over the asset life. Accuray reported that service revenue rose 3% year over year to USD 169.1 million in the first 9 months of fiscal 2026, while product revenue fell 21%, which shows how a slower capital cycle and a maturing installed base can weigh on fresh placements while raising service dependence. In Mexico, IMSS spent USD 8.7 million, to commission its first CyberKnife system in December 2025, which underlines how large these projects are even for public institutions. Because of this, the CyberKnife market remains concentrated in health systems that can absorb both capital and long-term service intensity.

Other drivers and restraints analyzed in the detailed report include:

• Expansion of Outpatient and Ambulatory Radiosurgery Delivery
• Faster Adoption of Hypofractionated Treatment Pathways
• Prior Authorization and Reimbursement Friction

Segment Analysis

The CyberKnife System segment held 48.31% of the CyberKnife market share in 2025, which kept hardware as the largest product category in the CyberKnife market. Services, however, are projected to grow at an 8.38% CAGR through 2031, making them the fastest-rising layer of the CyberKnife market by product type. This change matters because installed systems generate recurring revenue through preventive maintenance, remote diagnostics, training, and software upgrades even when new hardware orders slow. Accuray reported service revenue of USD 169.1 million in the first 9 months of fiscal 2026, up 3% year over year, while product revenue declined, which supports the view that the installed base is becoming more important to the CyberKnife market than single equipment sales.

Software is still the most dynamic layer inside the broader platform stack because it supports planning, adaptive delivery, and faster commissioning. Accuray received NMPA approval in China for the Accuray Precision Treatment Planning System in June 2024, and in September 2025 launched the Stellar solution, which brought adaptive radiotherapy capabilities together with CyberComm commissioning tools. That launch shows how the CyberKnife industry is moving toward a model where software, service, and workflow integration deepen customer retention after the initial sale. It also means procurement teams are placing more weight on lifetime ownership cost than on unit price alone. In practical terms, the CyberKnife market size for services is projected to expand at 8.38% CAGR through 2031, which signals that recurring post-sale revenue is becoming central to vendor economics.

Complete Report Scope:

• By Product Type
  • CyberKnife System
  • Software Solutions
  • Services
• By Indication
  • Tumor and Cancer
  • Vascular Malformation
  • Other Indications
• By End User
  • Hospitals & Academic Medical Centers
  • Independent Radiotherapy/Cancer Centers
  • Ambulatory/Outpatient Radiosurgery Centers
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 45.22% share in 2025, which gave the region the largest position in the CyberKnife market and the most established operating environment. The United States remained the anchor because of its large installed base, established CMS reimbursement codes for robotic image-guided radiosurgery, and long history of high-technology oncology procurement. Even in this mature setting, access is still expanding into community care, as shown by the October 2025 San Diego CyberKnife S7 launch, which was described as one of only 2 sites in California and the only one in Southern California. Mexico remained a smaller market, but its December 2025 public-sector installation through IMSS marked a meaningful regional step because it showed that government-backed procurement can support CyberKnife market development outside high-income systems.

Europe remains more concentrated by country and by site type, with academic centers playing a leading role in the CyberKnife market. Germany continued to be the region’s most established base, and Charité Berlin remained a prominent university hospital site for CyberKnife treatment. Austria added a fresh point of expansion in May 2025 when the CyberKnife Center Salzburg started SRS and SBRT patient treatments using the CyberKnife S7 system. That project also highlighted a structural supply gap, since Austria’s radiotherapy equipment availability remained 27% below the EU average, which supports room for further CyberKnife market growth in under-equipped systems. Across the region, compliance under EU medical device rules continues to add cost and operating discipline for both vendors and center operators.

Asia-Pacific is projected to grow at a 9.65% CAGR through 2031, which makes it the fastest-expanding regional block in the CyberKnife market. China’s January 2025 NMPA approval of the CyberKnife S7 system opened a much larger hospital base to next-generation deployment and improved the platform’s access to one of the world’s largest cancer care systems. In India, installations in Lucknow and Western Uttar Pradesh show that adoption is moving beyond top-tier metro centers, although regulatory approvals still shape commissioning timelines. Australia also became a visible growth market after the October 2025 Melbourne launch through a joint venture between 5D Clinics and Icon Group, with plans to expand across the East Coast. In the Middle East and Africa, Tawam Hospital introduced the first CyberKnife S7 deployment in Abu Dhabi and Kenya commissioned the first CyberKnife in sub-Saharan Africa, while South America remained early stage with Brazil and Colombia already active and Mexico joining the regional installed base in 2025.

List of Companies Covered in this Report:

• Accuray

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support